Tumor-activated sorafenib prodrug as well as preparation method and application thereof

By designing tumor-activated sorafenib prodrug, using ferrocene formic acid and thioketone molecules to combine sorafenib molecules, specific activation and oxygen generation at the tumor are achieved, and sorafenib is solved for normal cells The problem of accidental injury and tumor hypoxia significantly reduces the tumor's invasion and migration ability and improves the treatment effect on liver cancer.

CN118955576AActive Publication Date: 2024-11-15SHANDONG NORMAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411043540.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

Sorafenib lacks cell specificity, causing accidental damage to normal cells, and after inhibiting angiogenesis of liver cancer tissue, putting the tumor in an hypoxic state, enhancing the migration and invasiveness of the tumor.

Method used

A tumor-activated sorafenib prodrug was designed to generate oxygen by specifically activate molecular structure and Fenton reaction at the tumor, reducing the invasion and migration ability of the tumor, using ferrocene formic acid and thioketone molecules as the main body. Structure, combined with sorafenib molecules, a sorafenib prodrug that can activate cytotoxicity at the tumor is prepared.

Benefits of technology

Effectively kill liver cancer cells, reduce tumor invasion and migration ability, improve tumor oxygen supply, and enhance treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955576A_ABST
    Figure CN118955576A_ABST
Patent Text Reader

Abstract

The invention discloses a tumor-activated sorafenib prodrug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the tumor-activated sorafenib prodrug designed by the invention, a sorafenib molecule and a ferrocenecarboxylic acid molecule are taken as main structures, cytotoxicity can be specifically activated at a tumor, and compared with sorafenib, the tumor-activated sorafenib prodrug can better kill liver cancer cells; in addition, Fenton reaction is carried out in situ, oxygen is generated to improve hypoxia of tumors, and invasion and migration ability of the tumors is reduced; the Fenton reaction can generate hydroxyl free radicals with strong toxicity to kill liver cancer cells and assist in treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a tumor-activated sorafenib prodrug and a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Sorafenib is an FDA-approved oral drug that can be used to treat inoperable hepatocellular carcinoma. Since the toxicity of sorafenib lacks cell specificity, it is easy to accidentally injure normal cells. In addition, since sorafenib can inhibit the angiogenesis of liver cancer tissue, after using sorafenib, the blood vessels supplying liver cancer tissue are reduced, and the amount of oxygen obtained by liver cancer tissue is also reduced. This will put the liver cancer tissue in a state of "hypoxia", and in the "hypoxia" state, the ability of tumor cells to transform with other surrounding cells (i.e., tumor stromal cells) (this phenomenon is called "epithelial-mesenchymal transition", EMT) will be enhanced, and the enhancement of this ability will eventually lead to enhanced migration and invasiveness of the tumor, which means that the probability of tumor metastasis increases. Summary of the invention

[0004] In order to overcome the deficiencies of the prior art, the purpose of the present invention is to provide a tumor-activated sorafenib prodrug, which aims at the lack of specificity of sorafenib and designs a molecular structure design for specific activation at the tumor to avoid accidental injury to normal cells; in view of the tumor hypoxia caused by sorafenib, a molecular structure design capable of performing Fenton reaction at the tumor is designed to produce oxygen to improve hypoxia and generate highly toxic hydroxyl free radicals for auxiliary treatment; the improvement of tumor hypoxia reduces the invasion and migration ability of the tumor, which is conducive to better treatment of hepatocellular carcinoma.

[0005] In order to achieve the above object, the technical solution of the present invention is:

[0006] In a first aspect, the present invention provides a tumor-activated sorafenib prodrug, the structure of the sorafenib prodrug is shown in Formula I:

[0007]

[0008] The sorafenib prodrug is composed of sorafenib molecules and ferrocenecarboxylic acid molecules as the main structure, and can specifically activate cytotoxicity at the tumor site.

[0009] In a second aspect, the present invention provides a method for preparing a tumor-activated sorafenib prodrug, comprising the following steps:

[0010] Using an alkaline solution to hydrolyze sorafenib to prepare sorafenib carboxylic acid;

[0011] Preparation of thioketal molecules using 2-mercaptoethylamine hydrochloride;

[0012] An intermediate molecule is prepared by using a ferrocenecarboxylic acid molecule and a thioketal molecule;

[0013] The sorafenib carboxylic acid and the intermediate molecule are reacted to prepare a sorafenib prodrug.

[0014] In some embodiments, the specific steps of preparing sorafenib carboxylic acid by hydrolyzing sorafenib with an alkaline solution are: dissolving sorafenib and an alkaline solution in an organic solvent and heating; removing the organic solvent, adjusting the pH value to be neutralized to acidity, filtering and purifying the precipitated solid to obtain sorafenib carboxylic acid;

[0015] Furthermore, the alkaline solution is sodium hydroxide.

[0016] Furthermore, the molar ratio of sorafenib to alkaline solution is 1-5:25-35; preferably 1:30.

[0017] Furthermore, the organic solvent is anhydrous ethanol.

[0018] Furthermore, the heating is performed at 60-100° C. with stirring for 10-14 h; preferably, the heating is performed at 80° C. with stirring for 12 h.

[0019] Furthermore, the purification is performed using a silica gel column, and the eluent is a mixture of dichloromethane and methanol, with dichloromethane:methanol=10:1.

[0020] Furthermore, the sorafenib carboxylic acid (C 20 H 13 The structural formula of ClF3N3O4 is as follows:

[0021]

[0022] In some embodiments, the specific steps of using 2-mercaptoethylamine hydrochloride to prepare the thioacetal molecule are: dissolving 2-mercaptoethylamine hydrochloride in concentrated hydrochloric acid and stirring, adding acetone and dichloromethane in sequence, continuing to stir until a white solid precipitates, and filtering; stirring the filtered solid precipitate for a long time in an alkaline solution to react, and obtaining the thioacetal molecule after extraction.

[0023] Further, the 2-mercaptoethylamine hydrochloride is dissolved in concentrated hydrochloric acid at low temperature, wherein the low temperature is 0-5°C;

[0024] Furthermore, the long-term stirring has a stirring time of 10-14 hours.

[0025] Furthermore, the thioketal molecule (C7H 18 The structural formula of N2S2 is as follows:

[0026]

[0027] In some embodiments, the specific steps of using ferrocenecarboxylic acid and thioacetal molecules to prepare the intermediate molecule are: dissolving ferrocenecarboxylic acid in an organic solvent, adding 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, and thioacetal molecules while stirring, reacting at room temperature for a certain time, and purifying to obtain the intermediate molecule.

[0028] Furthermore, the molar ratio of ferrocenecarboxylic acid, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine and thioacetal is 1-2:1-2:2-3:3-5, preferably 1:1:2:3.

[0029] Furthermore, the reaction time at room temperature is 0.5-1..5h.

[0030] Furthermore, the purification is performed using a silica gel column, and the eluent is a mixture of ethyl acetate and petroleum ether, wherein the ratio of ethyl acetate to petroleum ether is 1:1.

[0031] Furthermore, the intermediate molecule (C 18 H 26 The structural formula of FeN2S2 is as follows:

[0032]

[0033] In some embodiments, the specific steps of reacting the sorafenib carboxylic acid and the intermediate molecule to prepare the sorafenib prodrug are:

[0034] Sorafenib carboxylic acid is dissolved in an organic solvent, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine and an intermediate molecule are added during stirring, reacted at room temperature, and purified after the reaction to obtain a sorafenib prodrug.

[0035] Furthermore, the molar ratio of sorafenib carboxylic acid, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, and the intermediate molecule is 1-2:1-2:2-3:3-4, preferably 1:1:2:3.

[0036] Furthermore, the reaction is carried out at room temperature and the reaction time is 1-2 hours.

[0037] Furthermore, the purification is performed by using a silica gel column, and the eluent is a mixture of dichloromethane and methanol, wherein the ratio of dichloromethane to methanol is 10:1.

[0038] Furthermore, the structure of the sorafenib prodrug is shown in Formula I:

[0039]

[0040] In a third aspect, the tumor-activated sorafenib prodrug obtained by the above preparation method is used in the preparation of drugs for treating liver cancer.

[0041] The present invention is used to treat any form or state of liver cancer, including but not limited to hepatocellular carcinoma (HCC), fibrolamellar carcinoma, hepatobiliary cancer (cholangiocarcinoma), angiosarcoma or hepatoblastoma. Preferably, the liver cancer is hepatocellular carcinoma.

[0042] The drug for treating hepatocellular carcinoma can be in the form of oral preparation or intravenous injection. The oral preparation is tablets, capsules, pills, granules, suspensions or drops.

[0043] The drug for treating hepatocellular carcinoma of the present invention can also be used in combination with other treatments, such as in a single dose, multiple doses, or sequential doses.

[0044] In a fourth aspect, the present invention further provides a pharmaceutical preparation, which comprises the above-mentioned tumor-activated sorafenib prodrug; preferably, the pharmaceutical preparation further comprises a pharmaceutically acceptable excipient or carrier.

[0045] The pharmaceutically acceptable excipient or carrier is at least one of a diluent, a disintegrant, a precipitation inhibitor, a glidant, a binder, a dispersant, a suspending agent, an isotonic agent, a thickener, an emulsifier, a preservative, a stabilizer, and the like.

[0046] The present invention provides a pharmaceutical formulation as described herein for use in a method of treating a human or animal subject in need thereof, in particular for use in a method of treating liver cancer in a subject.

[0047] In a fifth aspect, the present invention also provides a method for treating liver cancer in a human or animal subject in need thereof, the method comprising administering to the human or animal subject a therapeutically effective amount of a sorafenib prodrug or pharmaceutical formulation as described herein; and use of the sorafenib prodrug or pharmaceutical formulation described herein in the preparation of a medicament for treating liver cancer in a human or animal subject in need thereof.

[0048] One or some of the above technical solutions have the following advantages or beneficial effects:

[0049] The designed and synthesized sorafenib prodrug consists of sorafenib molecules and ferrocenecarboxylic acid molecules as the main structure, which can specifically activate cytotoxicity at the tumor site and kill liver cancer cells better than sorafenib.

[0050] The designed and synthesized sorafenib prodrug can undergo Fenton reaction in situ, producing oxygen to improve tumor hypoxia and reduce the invasion and migration ability of tumors; the Fenton reaction can generate highly toxic hydroxyl free radicals, kill liver cancer cells and assist in treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0052] Figure 1 Mass spectrum of the designed sorafenib prodrug;

[0053] Figure 2 are the NMR images of the intermediate molecule and the sorafenib prodrug, wherein a is the NMR image of the intermediate molecule, and b is the NMR image of the sorafenib prodrug;

[0054] Figure 3 The pictures are taken using the fluorescent probe DCFH-DA (taken using a confocal microscope) for detecting reactive oxygen species specifically. The PBS group was incubated without any material; the Sfb group was incubated with sorafenib in the liver cancer cells HePa 1-6; the Fca group was incubated with ferrocenecarboxylic acid in the liver cancer cells HePa 1-6; and the Sfb-Fca group was incubated with sorafenib prodrug molecules in the liver cancer cells HePa1-6.

[0055] Figure 4 The pictures are taken using the fluorescent probe AM / PI for live and dead cell detection (taken using a confocal microscope), where the PBS group was incubated without any material; the Fca group was incubated with ferrocenecarboxylic acid for HePa 1-6 liver cancer cells; the Sfb group was incubated with sorafenib for HePa 1-6 liver cancer cells; the Sfb-Fca group was incubated with sorafenib prodrug molecules for HePa 1-6 liver cancer cells;

[0056] Figure 5 The volume of tumors in different groups of mice was detected during in vivo treatment in the C57 black mouse model, among which the PBS group was mice not injected with any materials; the Fca group was mice injected with ferrocenecarboxylic acid; the Sfb group was mice injected with sorafenib; the Sfb-Fca group was mice injected with sorafenib prodrug molecules; and the Sfb+Fca group was mice injected with sorafenib and ferrocenecarboxylic acid. DETAILED DESCRIPTION

[0057] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0058] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present invention. Experimental steps not described in detail in the present invention are performed according to conventional experimental operations or according to product instructions.

[0059] Explanation of terms involved:

[0060] Sorafenib is the name of the drug, English name: Sorafenib, CAS number: 284461-73-0, Chinese name: 4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-urea]phenoxy}-pyridine-2-carboxylic acid methylamine, its structural formula is as follows:

[0061]

[0062] Prodrugs are inactive drugs.

[0063] 2-Mercaptoethylamine hydrochloride, CAS number: 156-57-0.

[0064] Ferrocenecarboxylic acid, CAS number: 1271-42-7.

[0065] HATU, Chinese name: 2-(7-azabenzotriazole)-N,N,N',N"-tetramethyluronium hexafluorophosphate, CAS number: 148893-10-1.

[0066] DIPEA, Chinese name: N,N-diisopropylethylamine, CAS number: 7087-68-5.

[0067] As introduced in the background technology, the toxicity of sorafenib lacks cell specificity, and excessive use of sorafenib will cause the tumor tissue to become a hypoxic environment. Under the "hypoxic" state, the transformation ability of tumor cells and other surrounding cells (i.e., tumor stromal cells) (this phenomenon is called "epithelial-mesenchymal transition", EMT) will be enhanced, thereby causing the tumor's invasion and migration capabilities to increase.

[0068] In order to solve the above technical problems, the present invention provides a tumor-activated sorafenib prodrug.

[0069] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0070] Example 1

[0071] The preparation method of sorafenib prodrug comprises the following steps:

[0072] 1. Sorafenib is hydrolyzed with sodium hydroxide to prepare sorafenib carboxylic acid:

[0073] Dissolve 1 mol of sorafenib and 30 mol of NaOH in 150 mL of anhydrous ethanol, and heat and stir at 80° for 12 hours. After the reaction is completed, use a rotary evaporator to dry the ethanol, add water to dissolve, and use 1M dilute hydrochloric acid to neutralize to pH = 5, and solid precipitates. After filtering the solid, dissolve it in dichloromethane solvent, mix with silica gel powder, use a rotary evaporator to dry it, and purify it with a silica gel column (eluent ratio dichloromethane: methanol = 10:1) to obtain sorafenib carboxylic acid (C 20 H 13 ClF3N3O4), whose structural formula is shown below:

[0074]

[0075] 2. Preparation of thioketal molecules:

[0076] 5.78 g of 2-mercaptoethylamine hydrochloride was dissolved in 4 mL of concentrated hydrochloric acid at 0°. After stirring for 10 minutes, 10 mL of acetone and 4 mL of dichloromethane were added in sequence. Stirring was continued for 10 minutes until a white solid (crude product of thioketal molecule) was precipitated and filtered. The precipitate was dissolved in an appropriate amount of methanol solvent. After it was fully dissolved, 10 mL of 6 M NaOH solution was added. After stirring at room temperature for 12 hours, 50 mL of dichloromethane solvent was added for extraction to obtain the thioketal molecule (C7H 18 N2S2), whose structural formula is shown below:

[0077]

[0078] 3. Use ferrocenecarboxylic acid and thioketal molecules to prepare intermediate molecules:

[0079] 1 mol of ferrocenecarboxylic acid was dissolved in an appropriate amount of dichloromethane solvent, and 1 mol of HATU, 2 mol of DIPEA and 3 mol of the above-prepared thioketal molecule were added during stirring. After reacting at room temperature for 1 hour, the sample was mixed with silica gel powder, dried by rotary evaporator, and purified by silica gel column (eluent ratio ethyl acetate: petroleum ether = 1:1) to obtain the intermediate molecule (C 18 H 26 FeN2S2), the corresponding NMR data are Figure 2 a, whose structural formula is shown below:

[0080]

[0081] 4. Using the sorafenib carboxylic acid (C20 H 13 ClF3N3O4) and the intermediate molecule prepared above (C 18 H 26 FeN2S2) to prepare the sorafenib prodrug molecule:

[0082] 1 mol of sorafenib carboxylic acid was dissolved in an appropriate amount of dichloromethane solvent, and 1 mol of HATU, 2 mol of DIPEA and 3 mol of the intermediate molecule were added during stirring. After reacting at room temperature for 1 hour, the sample was mixed with silica gel powder, dried by rotary evaporator, and purified by silica gel column (eluent ratio of dichloromethane: methanol = 10:1) to obtain the sorafenib prodrug molecule (C 38 H 37 ClF3FeN5O4S2), the corresponding mass spectrum and NMR data are Figure 1 and Figure 2 b, whose structure is shown in the following formula I:

[0083]

[0084] Example 2

[0085] Sorafenib prodrug (C 38 H 37 ClF3FeN5O4S2) cell experiment 1:

[0086] Experimental principle: The ferrocene group in the sorafenib prodrug can undergo a Fenton reaction under the action of hydrogen peroxide overexpressed in tumor cells to produce hydroxyl radicals (ROS).

[0087] Experimental plan: Hepatocellular carcinoma cells (HePa 1-6) were cultured in a cell confocal culture dish, and incubated with DCFH-DA kit probe (purchased from Beyotime, product number: S0033S) and 0.25mM sorafenib prodrug for 20 minutes. The production of ROS was photographed under an SP8 confocal microscope ( Figure 3 ).

[0088] like Figure 3 As shown, the experiment used the reactive oxygen species specific fluorescent probe DCFH-DA. The PBS group was incubated without any material; the Sfb group was incubated with sorafenib in the liver cancer cells HePa1-6; the Fca group was incubated with ferrocenecarboxylic acid in the liver cancer cells HePa 1-6; and the Sfb-Fca group was incubated with sorafenib prodrug molecules in the liver cancer cells HePa 1-6. Figure 3 It can be seen that the designed sorafenib prodrug molecule can effectively produce reactive oxygen hydroxyl radicals in liver cancer cell HePa 1-6.

[0089] Example 3

[0090] Sorafenib prodrug (C 38 H 37 ClF3FeN5O4S2) cell experiment 2:

[0091] Experimental principle: Due to the overexpression of ROS in cancer cells, the thioketone bond can be destroyed to release the Sorafenib drug. And the ferrocene group of the Sorafenib prodrug molecule can undergo Fenton reaction under the action of hydrogen peroxide overexpressed in tumor cells to produce hydroxyl free radicals (ROS), which further intensifies the destruction of the thioketone bond to release the Sorafenib drug. Sorafenib can effectively produce cytotoxicity to cancer cells, and chemotherapy combined with Fenton reaction can treat cancer.

[0092] Experimental plan: HePa 1-6 cells were cultured in a cell confocal culture dish and incubated with 0.25 mM sorafenib prodrug molecules for 24 hours, then the culture medium was aspirated and washed with PBS buffer. Calcein / PI cell activity and cytotoxicity detection kit (purchased from Beyotime, product number: C2015M) was used to incubate for 20 minutes, and the cytotoxicity experiment was photographed under an SP8 confocal microscope ( Figure 4 ).

[0093] like Figure 4 As shown, the live and dead cell detection fluorescent probe AM / PI was used in the experiment. The PBS group was incubated without any material; the Fca group was incubated with ferrocene carboxylic acid for HePa 1-6 liver cancer cells; the Sfb group was incubated with sorafenib for HePa 1-6 liver cancer cells; and the Sfb-Fca group was incubated with sorafenib prodrug molecules for HePa 1-6 liver cancer cells. Figure 4 It can be seen that the designed sorafenib prodrug molecule can effectively produce cytotoxicity in liver cancer cell HePa 1-6 in vivo.

[0094] Example 4

[0095] Sorafenib prodrug (C 38 H 37 In vivo therapeutic experiment on C57 black mouse model with ClF3FeN5O4S2).

[0096] C57 mice aged 4-5 weeks were randomly divided into 5 groups with 5 mice in each group to establish a tumor model. The PBS group was mice without any injection; the Fca group was mice injected with ferrocenecarboxylic acid; the Sfb group was mice injected with sorafenib; the Sfb-Fca group was mice injected with sorafenib prodrug molecules; and the Sfb+Fca group was mice injected with sorafenib and ferrocenecarboxylic acid. After inoculation of HePa 1-6 liver cancer cells, the tumors grew to 50 mm. 3 After intratumoral injection of materials (2.5 mM, 50 μl PBS), the changes in tumor volume were recorded every 2 days ( Figure 5 ).

[0097] Depend on Figure 5 As shown, the designed sorafenib prodrug significantly inhibited tumor growth and cured the tumor in vivo in the C57 black mouse model.

[0098] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A tumor-activated sorafenib prodrug, the structure of the sorafenib prodrug is shown in Formula I:

2. The method for preparing a tumor-activated sorafenib prodrug according to claim 1, characterized in that: The steps include: Using an alkaline solution to hydrolyze sorafenib to prepare sorafenib carboxylic acid; Preparation of thioketal molecules using 2-mercaptoethylamine hydrochloride; The intermediate molecule is prepared using ferrocenecarboxylic acid and thioketal molecules; The sorafenib carboxylic acid and the intermediate molecule are reacted to prepare a sorafenib prodrug.

3. The preparation method according to claim 2, characterized in that: The specific steps of preparing sorafenib carboxylic acid by hydrolyzing sorafenib with an alkaline solution are: dissolving sorafenib and an alkaline solution in an organic solvent and heating them, removing the organic solvent, adjusting the pH value to neutralize to acidity, filtering and purifying the precipitated solid to obtain sorafenib carboxylic acid; Or, the molar ratio of sorafenib to alkaline solution is 1-5:25-35; Or, the heating is heating and stirring at 68-188°C for 18-14h; preferably, the heating and stirring is heating and stirring at 88°C for 12h; Alternatively, the purification is performed using a silica gel column, and the eluent is a mixture of dichloromethane and methanol.

4. The preparation method according to claim 2, characterized in that: The specific steps of using 2-mercaptoethylamine hydrochloride to prepare the thioketal molecule are: dissolving 2-mercaptoethylamine hydrochloride in concentrated hydrochloric acid and stirring, adding acetone and dichloromethane in sequence, continuing to stir until a white solid precipitates, and filtering; stirring the filtered solid precipitate for a long time in an alkaline solution to react, and extracting to obtain the thioketal molecule; Or, the 2-mercaptoethylamine hydrochloride is dissolved in concentrated hydrochloric acid at low temperature, wherein the low temperature is 8-5°C; Or, the long-term stirring may be for 18-14 hours.

5. The preparation method according to claim 2, characterized in that: The specific steps of using ferrocenecarboxylic acid and thioacetal molecules to prepare the intermediate molecule are: dissolving ferrocenecarboxylic acid in an organic solvent, adding 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, and thioacetal molecules during stirring, reacting at room temperature for a certain time, and purifying to obtain the intermediate molecule.

6. The preparation method according to claim 5, characterized in that: The molar ratio of ferrocenecarboxylic acid, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, and thioacetal is 1-2:1-2:2-3:3-5, preferably 1:1:2:3; Or, the reaction time at room temperature is 8.5-1.5h; Or, the purification is performed using a silica gel column, and the eluent is a mixture of ethyl acetate and petroleum ether; Or, the structure of the intermediate molecule is as follows:

7. The preparation method according to claim 2, characterized in that: The specific steps of preparing the sorafenib prodrug by reacting the sorafenib carboxylic acid and the intermediate molecule are as follows: dissolving the sorafenib carboxylic acid in an organic solvent, adding 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine and the intermediate molecule during stirring, reacting at room temperature, and purifying after the reaction to obtain the sorafenib prodrug.

8. The preparation method according to claim 7, characterized in that: The molar ratio of sorafenib carboxylic acid, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, and the intermediate molecule is 1-2:1-2:2-3:3-4, preferably 1:1:2:3; Or, the reaction is carried out at room temperature for 1-2 hours; Alternatively, the purification is performed by using a silica gel column, and the eluent is a mixture of dichloromethane and methanol.

9. Use of the tumor-activated sorafenib prodrug according to claim 1 or the tumor-activated sorafenib prodrug obtained by the preparation method of any one of claims 2 to 8 in the preparation of a medicament for treating liver cancer, preferably, the liver cancer includes hepatocellular carcinoma, fibrolamellar carcinoma, hepatobiliary cancer, angiosarcoma or hepatoblastoma; more preferably, the liver cancer is hepatocellular carcinoma.

10. A pharmaceutical preparation comprising the tumor-activated sorafenib prodrug of claim 1; preferably, the pharmaceutical preparation further comprises a pharmaceutically acceptable excipient or carrier.

Citation Information

Patent Citations

  • Sorafenib sulfydryl derivative and application thereof

    CN112624967A

  • Immunophilin binding agents and uses thereof

    US20230063768A1